ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $73.66M fell 3.8% year over year, behind the +13.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.0% from the prior quarter. Over 3 fiscal years it compounded at +36.8% a year.

Context

  • Selling, general & admin amounted to 36.0% of revenue in FY2025, down 4.7 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $412.84M (+29.9%) for the fiscal year ending Dec 2026, a step up from the +27.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$73.66M-11.0% QoQ
Last fiscal yearDec 2025
$317.75M+27.3% YoY
LTMMar 2026
$314.87M+13.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.8%+19.6%+23.4 pp
1 year+27.3%+29.9%+2.6 pp
3-year CAGR+36.8%+15.7%-21.1 pp
5-year CAGR+11.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
317.75M USD
Year-over-year change
+27.3%
4-year CAGR
+39.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ANIP compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.2% is the 4th highest of 9, against a peer median of +6.5%.
  • Selling, general & admin amounts to 34.1% of revenue for ANIP, versus a peer median of 26.5%.
ANIP Competitors
Selling, General & Admin for ANIP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹112.14B INR+14.7%+18.2%33.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$4.13B USD+9.9%+4.9%23.8%
VTRSViatris Inc.LTM Jun 2026$3.98B USD+1.3%-3.2%27.0%
BHCBausch Health Companies Inc.LTM Jun 2026$3.45B USD+0.5%+10.7%31.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$571.86M USD+16.7%+9.6%18.3%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$314.87M USD+13.2%+36.8%34.1%
EOLSEvolus, Inc.LTM Mar 2026$216.13M USD+3.1%+15.9%71.6%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$206.83M USD-15.5%+17.1%26.0%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$131.9M USD+35.5%+24.9%18.3%
HROWHarrow Health, Inc.LTM Mar 2026$86.54M USD——32.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$33.33M USD—+8.3%24.7%
Peer median (excluding ANIP) —+6.5%+10.7%26.5%

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.